Shandong Sinobioway Biomedicine Co Ltd (002581) — Strategic Asset Allocation Index
Shandong Sinobioway Biomedicine Co Ltd (002581) has a Strategic Asset Allocation Index of 25.8% as of September 2023. Strategic assets (PP&E of CN¥650.15 Million plus long-term investments of CN¥-) total CN¥650.15 Million, measured against net assets of CN¥2.52 Billion. A higher index reflects capital-intensive or investment-heavy strategies where strategic assets dominate the equity base.
SAAI
Strategic Assets
PP&E
Net Assets
Shandong Sinobioway Biomedicine Co Ltd Strategic Asset Allocation Index (2007–2022)
This chart shows how Shandong Sinobioway Biomedicine Co Ltd's Strategic Asset Allocation Index has evolved across 16 annual periods from 2007 to 2022. As of September 2023, the index stands at 25.8%, representing strategic assets of CN¥650.15 Million against net assets of CN¥2.52 Billion CNY. Explore cash efficiency ratio of Shandong Sinobioway Biomedicine Co Ltd to assess how effectively this company generates cash.
Annual Strategic Asset Allocation Index for Shandong Sinobioway Biomedicine Co Ltd (2007–2022)
The table below presents the year-by-year Strategic Asset Allocation Index for Shandong Sinobioway Biomedicine Co Ltd from 2007 to 2022, covering 16 annual filings. Each row shows PP&E, long-term investments, strategic assets combined, net assets, the index percentage, and the change in percentage points compared to the prior year. For the full company profile including market capitalisation, see 002581 company net worth.
| Year | SAAI | Strategic Assets (CNY) | PP&E | LT Investments | Net Assets | Change (pp) |
|---|---|---|---|---|---|---|
| 2022 | 28.6% | CN¥705.47 Million | CN¥705.47 Million | CN¥- | CN¥2.47 Billion | ▼ -0.3 pp |
| 2021 | 28.9% | CN¥713.76 Million | CN¥713.76 Million | CN¥- | CN¥2.47 Billion | ▼ -2.4 pp |
| 2020 | 31.3% | CN¥684.72 Million | CN¥684.72 Million | CN¥- | CN¥2.19 Billion | ▼ -1.4 pp |
| 2019 | 32.7% | CN¥780.90 Million | CN¥780.90 Million | CN¥- | CN¥2.39 Billion | ▼ -10.2 pp |
| 2018 | 42.9% | CN¥1.21 Billion | CN¥775.26 Million | CN¥434.74 Million | CN¥2.82 Billion | ▲ +10.1 pp |
| 2017 | 32.8% | CN¥958.15 Million | CN¥504.92 Million | CN¥453.22 Million | CN¥2.92 Billion | ▼ -0.2 pp |
| 2016 | 33.0% | CN¥835.20 Million | CN¥482.19 Million | CN¥353.01 Million | CN¥2.53 Billion | ▲ +0.9 pp |
| 2015 | 32.1% | CN¥688.46 Million | CN¥475.96 Million | CN¥212.50 Million | CN¥2.14 Billion | ▲ +10.5 pp |
| 2014 | 21.6% | CN¥162.14 Million | CN¥162.14 Million | CN¥- | CN¥749.40 Million | ▼ -4.8 pp |
| 2013 | 26.5% | CN¥195.54 Million | CN¥195.54 Million | CN¥- | CN¥738.31 Million | ▲ +4.1 pp |
| 2012 | 22.4% | CN¥157.95 Million | CN¥157.95 Million | CN¥- | CN¥704.41 Million | ▲ +6.6 pp |
| 2011 | 15.8% | CN¥106.08 Million | CN¥106.08 Million | CN¥- | CN¥672.28 Million | ▼ -32.0 pp |
| 2010 | 47.8% | CN¥84.78 Million | CN¥84.78 Million | CN¥- | CN¥177.34 Million | ▼ -1.4 pp |
| 2009 | 49.2% | CN¥63.79 Million | CN¥63.79 Million | CN¥- | CN¥129.71 Million | ▼ -6.3 pp |
| 2008 | 55.5% | CN¥64.42 Million | CN¥64.42 Million | CN¥- | CN¥116.12 Million | ▲ +10.7 pp |
| 2007 | 44.8% | CN¥37.59 Million | CN¥37.59 Million | CN¥- | CN¥83.94 Million | — |